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Abstract
The purpose of the study was to identify differential trajectories of patient compliance in a
clinical trial and to determine demographic and health risk factors associated with compliance
trajectory membership. The data was obtained from an 18 month, double-blinded, placebocontrolled trial looking at the long-term impact of increased dietary protein on bone mass in
older men and women. Two hundred and eight subjects were randomized to either a protein
treatment or carbohydrate placebo group. Statistical analysis utilized a group-based trajectory
modeling framework to identify distinct clusters of individuals who follow similar compliance
trajectories over time. Post hoc analysis using multinomial and standard logistic regression
models were conducted to incorporate risks factors associated with compliance group
membership. A four-group trajectory model was selected and determined that reported adverse
event was a significant risk factor. This analysis will provide supplementation to the standard
intention-to-treat analysis to understand how efficacy is driven by compliance and will pave the
way to improve compliance in subsequent protein-supplemented trials.
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1. Introduction
Osteoporosis, a skeletal disorder characterized by low bone density and micro-architectural
deterioration of bone tissue, affects over 10 million persons in the United States.1 This
predisposition increases the risk of osteoporotic fractures, a major cause of morbidity and
disability in the elderly.2 It is projected that by 2025, the direct costs of inpatient medical
services and nursing home care will exceed $27 billion in hip fractures alone, not to mention
indirect costs associated with loss of productivity and a reduction in quality of life due to
disability.3,4 The World Health Organization (WHO) defines osteoporosis based on a
measurement of bone mineral density (BMD), where individuals with BMD levels more than 2.5
standard deviations below the young adult reference mean are considered to have osteoporosis.5
The dual-energy X-ray absorptiometry (DEXA) is currently regarded as the gold standard to
measure BMD.5

Nutrition plays an important role in the development and maintenance of bone mass and the
prevention and treatment of osteoporosis.1,2,5,6 Calcium is one of the main bone-forming minerals
and contributors in the attainment of peak bone mass, and vitamin D is also required for optimal
calcium absorption.1,2,6 There is evidence to suggest the importance of dietary protein as a key
nutrient in the regulation of calcium metabolism and homeostasis.7–11 A systematic review of 18
cross sectional surveys indicated a significantly positive association between dietary protein and
lumbar spine BMD, a clinically meaningful outcome (rpooled =0.143, 95% CI: 0.10, 0.20).12 This
was validated through a meta-analysis of six randomized placebo-controlled trials, indicating a
positive influence of protein supplementation on lumbar spine BMD.12 However, the long-term
effects of dietary protein on skeletal health and fracture risk remains uncertain.12 Furthermore, in
many of these intervention-based trials, compliance with respect to protein supplementation has
not been thoroughly examined. Since elevated BMD is demonstrated through increased dietary
protein consumption, BMD is arguably driven by compliance. This suggests a dose-response
relationship between compliance and BMD; better compliance of dietary protein results in a
greater increase in BMD. Therefore, monitoring compliance is essential to establishing clinical
efficacy.13 Identifying the long-term patterns of compliance may pave the way to determine
thresholds for treatment efficacy.14
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This provides the motivation for an analysis to (1) identify differential trajectories of patient
compliance in a long-term randomized clinical trial (RCT) and to (2) determine demographic and
health risk factors associated with compliance trajectory membership. The analysis will provide
insight to develop strategies for future RCTs to improve patient compliance in proteinsupplemented trials. The analysis will also provide supplementation to the standard intention-totreat (ITT) analysis.15 The principle of ITT requires that all subjects be analyzed based on their
original randomization scheme regardless of their confounding experience.16 The proposed
analysis may help to explain the therapeutic mechanisms of the treatment and to address different
types of questions that are not explained by an ITT analysis.16 For example, if poor compliance
can be traced to an unpleasant aftertaste of the treatment, this can be easily remedied by
motivating subjects to focus on the long-term benefits despite the unpleasant aftertaste or even
improving the taste of the treatment in subsequent studies.16

Statistical methods, such as group-based trajectory modeling (GBTM), have been developed to
identify distinct clusters of individuals who follow similar trajectories over time.17 GBTM has
been used in the fields of psychology and sociology, and more recently, it has been seen in
clinical studies to capture heterogeneity in treatment responses longitudinally.18,19 GBTM draws
from well developed methodologies including hierarchical and latent class models.20 Several
studies have looked at patient compliance in a variety of clinical applications using GBTM,14,21–
23

which adds to the motivation in using this methodology for the proposed analysis.

2. Materials and Methods

Study Participants and Procedures
A data set was obtained from an 18 month, double-blinded, placebo-controlled trial looking at
the long-term impact of increased dietary protein on bone mass in older men and women.24 Twohundred and eight English speaking men and women over the ages of 70 and 60 years were
selected for the trial, respectively. The subjects were recruited from central and southern-central
Connecticut, and the study sites were located at Yale University and the University of
Connecticut’s Health Center (UCHC). Subjects were selected because they naturally consumed a
moderately low, but adequate protein diet (0.6-1.0 g/kg). After baseline measurements (BMD,
8

heart rate, blood pressure, and height and weight) and screening and safety biochemistries from
blood and urine samples were taken at the initial visit, eligible subjects were invited back for
randomization proceedings. Subjects were randomized to either a protein treatment or
carbohydrate placebo group. Both supplements were formulated to be identical in appearance,
taste, texture, and caloric content. It was expected that subjects consume 40 g of the protein or
carbohydrate powder daily by mixing it into their food or drink. Registered dietitians provided
nutritional counseling during the initial and follow-up visits to (1) stabilize the subjects’ calcium
and vitamin D intake and to cease all other nutritional supplements that may affect bone
homeostasis, (2) incorporate the powder supplements into their diets and provide weight
management, and (3) monitor compliance of treatment. After randomization, subjects were
followed up after 1.5, 3, 6, 9, 12, 15, and 18 months. It should be noted that at the time the data
was received, the study was still active. Therefore, the analysis was performed blinded and did
not take into account treatment groups.

Measures
For the purposes of this analysis, the outcome variable was percent compliance. The following
covariates were considered as potential predictors of compliance trajectory membership: baseline
DEXA lumbar vertebrae 2-4 (L2-4) BMD, BMD T-score, age, gender, study site, reported
adverse event, physical function measured by the Estimated Populations for Epidemiologic
Studies of Elderly (EPESE) battery, and self-reported history of depression and/or anxiety.
(1) Percent Compliance
After randomization, patients were dispensed a batch of the supplement either containing
the protein or carbohydrate powder. It was expected that subjects consume 40 g of the
powder daily, and so the appropriate amount was dispensed and recorded accordingly.
Subjects were asked to bring any unconsumed powder with them during follow-up visits
to be weighed. The amount consumed was calculated as the amount dispensed during the
previous visit minus the unconsumed amount during the follow-up visit. The expected
amount consumed was calculated as 40 g of powder multiplied by the days between each
visit. Therefore percent compliance was calculated as:
Percent Compliance = (Amount Consumed / Expected Amount) x 100
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Compliance data was available after the second visit, and repeated measurements were
taken during visits 3, 4, 5, 6, 7, 8, and 9 (i.e. during months 1.5, 3, 6, 9, 12, 15, and 18).
Occasionally, there were subjects who consumed more than 40 g of powder daily, on
average. Since these subjects exceed the expected amount and therefore were fully
compliant, they were considered as having one-hundred percent compliance. Conversely,
missing data from subjects that had dropped out of the study or stopped treatment but
remained in the study for follow-ups were considered to be fully non-compliant. These
subjects were recorded as having zero percent compliance.
(2) DEXA L2-4 BMD and T-score
The DEXA L2-4 BMD (g/ cm2) was the primary endpoint of the clinical trial.
Measurements were taken initially during the screening visit and remeasured after 9 and
18 months (visits 6 and 9). Baseline BMD was only considered for this analysis to
evaluate the initial disease severity. In addition, the T-score, a clinically relevant tool for
diagnosing osteoporosis, was also considered. A T-score is defined as the number of
standard deviations from the mean BMD in relation to a young healthy adult population.5
Since subjects were considered to have osteoporosis if their T-score was less than -2.5,
this variable was categorized to ≤ -2.5 as having clinically diagnosed osteoporosis and
> -2.5 as having moderately low (osteopenia) to normal BMD levels.
(3) Demographic and Other Health Measurements
Since women are at greater risk of developing osteoporosis,25 the trial over-sampled
women to men that were 60 and 70 years of age or older, respectively. The study sites
were located either at Yale University or UCHC. Adverse events were recorded at
baseline and follow-up visits. An adverse event is defined as any injurious falls to the
ground that resulted in bruises, strains, cuts and abrasion, back pain, and/or fractures.24 A
record of any adverse event and its severity was kept throughout the trial. The baseline
reported adverse event was only used in the analysis. Self-reported history of depression
and/or anxiety was also considered as relevant predictor. Finally, physical performance
among older populations was measured by the EPESE battery, which consisted of three
domains of lower extremity function to assess gait speed, standing balance, and time to
rise from a chair five times.26–28 Within each domain, a score of 0 denoted an inability to
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complete the test, while a score of 4 represented the highest level of performance; the
maximum total EPESE score was 12.28

3. Statistical Analysis

Statistical analysis encompassed (1) descriptive statistics of the study characteristics, (2) model
selection for determining the compliance trajectory groups using GBTM, and (3) statistical
inference for determining predictors associated with compliance trajectory membership using
multinomial and standard logistic regression models. All data analysis was carried out using SAS
version 9.2 and PROC TRAJ, a SAS macro for GBTM developed by Bobby L. Jones.19

Group-Based Trajectory Modeling
Group-based trajectory modeling (GBTM), also referred to as latent class growth modeling, is a
statistical tool used to identify distinct clusters of individuals, called trajectory groups, who
follow a similar developmental trajectory on an outcome of interest.17,19 Trajectory groups can be
thought of as unobserved (latent) longitudinal strata where population variability is captured by
the differential trajectories across groups.17,29 GBTM uses a semi-parametric group-based
approach that draws from two well-developed methodologies – hierarchical modeling and latent
curve analysis.20 The key difference among these models is that hierarchical and latent class
models utilizes multivariate continuous distributions to explain the population-level variability in
growth, while GBTM uses a multinomial-based strategy to identify relatively homogeneous
clusters of developmental trajectories.20 GBTM is a special case of growth mixture models
(GMM) in that it assumes no random effects in each of the group’s trajectories; GMM relaxes
this assumption and allows for variation within each of the trajectory groups.17,30 GBTM has
been widely used in the fields of developmental and abnormal psychology as well as modeling
behavior in sociological and criminological studies.19 More recently, GBTM has been applied to
clinical research to map the developmental course of symptoms and to assess heterogeneity in
response to clinical interventions.17
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Derivation of the Group-Based Trajectory Model19,31,32
Let 𝑌𝑖 = {𝑦𝑖1 , 𝑦𝑖2 , 𝑦𝑖3 … 𝑦𝑖𝑇 } denote the repeated measurements of individual i over T

measurements. Since measurements are reassessed at each visit t (i.e. 1st, 2nd, 3rd visit, etc.), it is

expected that the number of visits be the same across individuals. GBTM assumes that
individuals fall within a particular group J such that
𝐽

𝐽

𝑗=1

𝑗=1

𝑃(𝑌𝑖 ) = � 𝜋𝑗 𝑃(𝑌𝑖 |𝐽 = 𝑗) = � 𝜋𝑗 𝑃𝑗 (𝑌𝑖 )

where 𝜋𝑗 is the probability of membership in group j, and 𝑃 𝑗 (𝑌𝑖 ) is the conditional probability of
𝑌𝑖 given membership in group j. The model makes a strong assumption that measurements for
individual i are independent of each other, conditional on membership in group j. Therefore,

𝑃 𝑗 (𝑌𝑖 ) = ∏𝑇𝑡=1 𝑝 𝑗𝑡 (𝑦𝑖𝑡 ). 𝜋𝑗 is estimated using a multinomial logit function to ensure that the
probabilities fall between 0 and 1:

𝜋𝑗 =

𝑒 𝜃𝑗

∑𝐽𝑗=1 𝑒 𝜃𝑗

where 𝜃1 is initialized at 0. GBTM is able to handle continuous (censored normal), count (zeroinflated Poisson), and binary outcome data by selecting a form of 𝑝 𝑗𝑡 (𝑦𝑖𝑡 ) to fit the appropriate

data type. For continuous data, GBTM uses a polynomial relationship between the outcome and
time variable:
∗𝑗

∗𝑗

𝑗

𝑗

𝑗

𝑗

𝑗

𝑦𝑖𝑡 = 𝛽0 + 𝛽1 𝑇𝑖𝑚𝑒𝑖𝑡 + 𝛽2 𝑇𝑖𝑚𝑒𝑖𝑡2 + 𝛽3 𝑇𝑖𝑚𝑒𝑖𝑡3 + 𝛽4 𝑇𝑖𝑚𝑒𝑖𝑡4 + 𝜀𝑖𝑡

where 𝑦𝑖𝑡 is a latent variable and link between the outcome and time variable, and 𝜀𝑖𝑡 is a random
error term that follows a normal distribution with mean of zero and constant variance 𝜎 2 . Many
statistical packages that performs GBTM allows specification of the order trajectories up to the
fourth degree polynomial.19,30,31

Model Selection of Compliance Trajectories using PROC TRAJ
GBTM can be applied to a variety of statistical packages including SAS and Mplus.19,30,31 For the
purposes of this analysis, PROC TRAJ, a SAS macro developed by Bobby L. Jones19 was used
to perform GBTM to estimate the compliance trajectories. PROC TRAJ assigns group
membership to each individual where the posterior probability of membership to that group is the
12

highest.19 Parameter estimates are based on maximum likelihood via the quasi-Newton
optimization procedure, and standard errors are approximated by a fist-order Taylor series
expansion.23 PROC TRAJ allows specification of the trajectories up to the fourth degree
polynomial.19,31 It includes subjects with missing longitudinal data and time-varying covariates;
however missing time-stable covariates are excluded from the analysis.19 Covariates can be
incorporated into the model either by adding them simultaneously in the PROC TRAJ statement,
or by performing post-hoc analysis using a multinomial logistic regression model. In this
analysis, both methods were performed to compare the consistency of the results.

Model selection involved a two-step process to determine the best model for each trajectory
group (i.e. best model containing 1-, 2-, 3-group trajectories, etc.) and the best overall model
with PROC TRAJ. The strategy outlined by Andruff et al.32 to determine the best model for each
trajectory group utilized a combination of visual inspection of the fitted compliance trajectories
overlaid with the mean trajectories at each time point, and tests of significance on whether or not
the time parameter estimates differed from zero. The significance level α was set at 0.05. For
each trajectory group, a third order polynomial model was fitted. A new model was refitted of
increased or decreased order depending on the significance of the third order parameter
estimates. This process was repeated until the highest order term achieved significance, and the
fitted model appeared adequate from the trajectory plot. Once a best model was chosen for each
trajectory group, the best overall model was selected using the Bayesian Information Criteria
(BIC) and the log Bayes factor to compare models. The log Bayes factor is approximated as:
log 𝐵𝑎𝑦𝑒𝑠 𝑓𝑎𝑐𝑡𝑜𝑟 = 2𝑙𝑜𝑔𝑒 (𝐵10 ) ≈ 2(∆𝐵𝐼𝐶)

where ∆𝐵𝐼𝐶 is the difference between the BIC of the larger model (alternative) model and the

BIC of the smaller (null) model.19 The log Bayes factor is interpreted as the degree of evidence
favoring the larger model and is shown in the table below.
Interpretation of the Log Bayes Factor
Log Bayes Factor
Evidence against H0
0 to 2
Weak
2 to 6
Positive
6 to 10
Strong
> 10
Very Strong
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To ensure that PROC TRAJ accurately assigned each individual to the appropriate trajectory
group, Nagin outlined four criteria to assess model adequacy: (1) the estimated probability of
group membership (𝜋�𝑗 ) should correspond closely to the proportion classified in that group based
on the highest posterior probability, (2) the confidence intervals around 𝜋�𝑗 should be reasonably
tight, (3) the average posterior probability (AvePP) of group membership for individuals

assigned to each group should exceed the 0.7 threshold, and (4) the odds of correct classification
(OCC) should exceed the minimum threshold of 5.17,18 For each group j, the OCC is calculated
as:
𝑂𝐶𝐶𝑗 =

𝐴𝑣𝑒𝑃𝑃/(1 − 𝐴𝑣𝑒𝑃𝑃)
𝜋�𝑗 /(1 − 𝜋�𝑗 )

Simultaneous and Post-hoc Analysis using Multinomial and Standard Logistic Regression
GBTM allows the group membership probabilities to vary as a function of time-stable
characteristics for an individual, and therefore covariates can be added simultaneously in the
PROC TRAJ statement to predict trajectory group membership.31 Measured covariates were
included in the model simultaneously to determine the impact of a given risk factor on the
probability of group membership in a specified trajectory group compared to a reference group.31
Given that the trajectory groups followed a multinomial distribution, post-hoc analysis using
multinomial logistic regression was also conducted to determine whether the measured
covariates were significant predictors of compliance trajectory group membership. The results of
the simultaneous and post-hoc analysis were compared for consistency. Furthermore, the groups
in the multinomial analysis were collapsed into a binary outcome variable indicating compliant
or non-compliant subjects. A standard logistic regression model was then performed to take into
account potential predictors for compliance. The Hosmer and Lemeshow Chi-square test for
goodness of fit was used to assess model adequacy, and the R2 and max-rescaled R2 was also
reported. Since R2 only achieves a maximum value of less than 1 when discrete variables are
included in a logistic regression model, the max-rescaled R2 provides a more accurate assessment
of model fit.33
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3. Results

Description of the Sample
Two-hundred and eight subjects were considered for the analysis to identify differential
trajectories of patient compliance and to determine risk factors associated with compliance group
membership. A description of the study participants can be found in Table 1. The mean age of
the subjects was 69.8 ± 6.2 years. As females are at higher risk of developing osteoporosis, they
were over-sampled and comprised of 85.6% of the study subjects. The majority of the subjects
(92.2%) had a T-score greater than -2.5, indicating that they did not have clinically diagnosed
osteoporosis at the beginning of the study. The mean EPESE score was 11.3 ± 1.1. Eighty-two
subjects reported an adverse event at baseline, while only 23 reported any history of depression
and/or anxiety.

Model Selection for Determining Compliance Trajectory Groups
Model selection for GBTM was assessed by comparing the BIC, log Bayes factor, and estimated
group proportions for five trajectory models (i.e. 1-, 2-, 3-, 4-, and 5-group models) (Table 2). A
6-group model failed to achieve convergence and was not included in the model selection. The
second group of the 5-group model contained only 2.14% of the total sample; therefore, the
sample size was not large enough to perform further analysis with multinomial logistic
regression. As a result, the 4-group model was chosen as the best model as it identified four
distinct trajectories with estimated group proportions well over the 5% threshold (Group 1:
23.5%, Group 2: 36.9%, Group 3: 19.8%, and Group 4: 19.8%).
A plot of the individual trajectories of percent compliance at each visit (Figure 1) indicated a
large degree of heterogeneity among the subject-specific percent compliance. After performing
GBTM, the fitted model was able to identify four distinct trajectory groups (Figure 2). Group 1
(red) was identified as “severely noncompliant.” Percent compliance within group 3 (blue)
decreased over time and these subjects were termed “delayed noncompliant.” Groups 2 (green)
and 4 (black) showed consistently moderate to high levels of compliance and were identified as
“moderately compliant” and near-perfect compliant” subjects, respectively. For comparison, a
panel of the 1-, 2-, 3-, and 5-group fitted models can be found in Figure 3.
15

The parameter estimates of the differential trajectories over time from the 4-group model are
shown in Table 3. The estimates of the highest degree polynomial within each group were found
be to significant (p < 0.001). To ensure that GBTM accurately assigned each individual to the
appropriate trajectory group, diagnostics were performed to check for model adequacy in Table
4. The estimated probabilities of group membership and the proportion classified to that group
showed close correspondence with each other. The width of the 95% confidence intervals of the
estimated probabilities appeared reasonably narrow, and the AvePP and OCC significantly met
the minimum thresholds of 0.7 and 5, respectively. Therefore, the diagnostics suggest that
GBTM was successful in accurately assigning each individual to the appropriate trajectory
group.

Predictors of Compliance Group Membership
Bivariate analysis of the study characteristics across the four trajectory groups is shown in Table
5. There were no significant associations between the compliance trajectory groups and the study
characteristics. Although not significant (p = 0.268), there were a greater proportion of subjects
with clinically diagnosed osteoporosis (T-score ≤ -2.5) among the severely (14.6 %) and delayed
(7.7%) noncompliant groups compared to the moderately (5.3%) and near-perfect compliant
groups (4.8%). The continuous DEXA measurement for BMD showed a consistent and slightly
more significant association (p = 0.092). Over half of the subjects within the delayed
noncompliant group (53.7%) reported an adverse event at baseline in comparison to the severely
noncompliant (32.7%), moderately compliant (36.8%), and near-perfect compliant (38.1)
subjects (p-value = 0.198).

PROC TRAJ has the capabilities to simultaneously identify differential trajectory groups and
take into account potential risk factors; however, when this was applied, convergence was not
achieved past two trajectory groups. Therefore, the results of the post hoc analysis were only
shown. One-hundred and sixty eight subjects with complete data were included in multinomial
logistic regression. Given that the T-score calculation was based off of the DEXA BMD and
therefore were highly correlated with each other, two separate models were performed. Table 6
shows the multivariate regression model that includes the BMD T-score (model 1), while Table 7
shows the model containing DEXA BMD (model 2).
16

The near-perfect compliant group was set as the reference group. None of the predictors
measured were found to be significant for model 1. When controlling for all other variables,
subjects who were severely noncompliant were 3.36 times more likely to have clinically
diagnosed osteoporosis (T-score ≤ -2.5) compared to those with near-perfect compliance (p =
0.176, 95% CI: 0.58, 19.34). Subjects with delayed noncompliance were more likely to report an
adverse event compared to subjects with near-perfect compliance (AOR = 2.27, 95% CI: 0.81,
6.34). On the other hand, DEXA BMD was found to be significant in model 2 (p = 0.036). The
severely (AOR = 0.26, 95% CI: 0.02, 3.89) and delayed (AOR = 0.64, 95% CI: 0.04, 11.02)
noncompliant groups were associated with lower BMD levels, while the moderately compliant
group (AOR = 6.66, 95% CI: 0.67, 65.8) showed increased BMD levels compared to the nearperfect compliant group. However, none of these estimates were significant, and the wide 95%
confidence intervals suggest that the reliability of the estimates is questionable. The significance
of the Wald Chi-square test implies significant associations for DEXA BMD comparing a
different reference group.

Since the severely and delayed noncompliant groups were presumably represented by
noncompliant subjects, and the moderately and near-perfect compliant groups as the compliant
subjects, the four groups were collapsed into a binary outcome. The probability of
noncompliance (i.e. comparison of noncompliant versus compliant group) was modeled using
standard logistic regression for models 1 and 2 (Tables 8 and 9). For both models, reported
adverse event was significantly associated with noncompliance (model 1: p = 0.033, model 2:
p = 0.35). Noncompliant subjects were 51% less likely to have reported an adverse event
compared to compliant subjects (model 1: AOR = 0.49, 95% CI: 0.25, 0.94, model 2: AOR =
0.49, 95% CI: 0.26, 0.95). However, the max-rescaled R2 of both multinomial (model 1: maxrescaled R2 = 0.164, model 2: max-rescaled R2 = 0.173) and standard logistic regression (model
1: max-rescaled R2 = 0.075, model 2: max-rescaled R2 = 0.082) models did not indicate an
adequate fit of the data, suggesting that other important risk factors were overlooked in
explaining the variability of the compliance trajectory groups.
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4. Discussion
GBTM was able to accurately identify four distinct compliance trajectory groups – severely
noncompliant, delayed noncompliant, moderately compliant, and near-perfect compliant groups.
However, because the parameter estimates for the risk factors did not achieve convergence when
added simultaneously to PROC TRAJ, the results of the simultaneous and post hoc analysis were
not compared. Jones argues that the post-hoc analysis does not account for the uncertainty in
group assignment and this could lead to bias; incorporating the predictors simultaneously
accounts for this automatically.19 Nonetheless, the procedure was shown to accurately identify
four distinct trajectory groups that follow a multinomial distribution based on the model
diagnostics for GBTM, and so the post hoc analysis was justified.

While there were no significant predictors of compliance group membership within the first
multinomial logistic model, DEXA BMD was found to be a significant predictor within the
second model. The wide variability around the 95% confidence intervals as well as the limited
number of subjects diagnosed with osteoporosis, on the other hand, suggest that the estimates
may not be reliable. As a result of the inclusion/exclusion criteria, relatively healthy subjects
were selected for the trial. This was evident as subjects had a mean EPESE score of 11.3, and
these scores were found not to be statistically different across the four compliance groups (p =
0.719). The main inclusion criterion was that they naturally consumed a moderately low, but
adequate protein diet. The trial excluded subjects with a BMD T-score of < -2.5 with the
exception of subjects who declined treatment for anti-osteoporotic medications throughout the
trial. Thus, only 16 out of 208 subjects were found to have clinically diagnosed osteoporosis.
This greatly limits the statistical power to conduct a multinomial logistic regression analysis and
to compare the four compliance groups. GBTM is preferable when the sample size is greater
than 300,18 and so this adds to a limitation in the analysis.

The nature of the clinical trial also limited the analysis in terms of potential risk factors that
could have been analyzed to predict compliance group membership. The trial restricted subjects
to those with normal BMI levels (i.e. excluded BMI levels < 19 and > 32). An investigation of
whether or not subjects with low BMI were more likely to comply with the treatment protocol
18

compared to those with normal to high levels would have provided much insight. Data on
reported history of gastrointestinal disorders (i.e. Crohn’s disease, colitis, ulcers) was also
available to determine whether the supplements had an adverse effect on these individuals,
making them less likely to be compliant. Unfortunately, there were not enough subjects that
responded to these questions, and so this was not considered in the analysis. Socioeconomic
status (SES), measured by education level, might also have been an important predictor as there
is a direct correlation between education and health.34 Subjects with higher education levels are
more likely to be health conscious, and so they might be motivated to take the supplements
regularly if they knew it would be beneficial to their health. However, subjects within the clinical
trial comprised of mainly retired and working class individuals, and so SES data was not
available.

A major limitation to this analysis was that the clinical trial was still active at the time the data
was received. As a result, the analysis did not take into account the treatment effect as a predictor
because the study had been blinded to the treatment allocation. Data on the treatment group
would have provided insight to uncover potential discrepancies in compliance between the
protein and carbohydrate groups. If it was shown that subjects who received the protein
treatment were more likely to fall within the noncompliant groups (i.e. severely and delayed
noncompliance) compared to the compliant groups (i.e. moderate and near-perfect compliance),
this may help to explain why the treatment was not efficacious to increase BMD levels. It is
possible that efficacy for the treatment effect was undermined by compliance. Equally, if
subjects who received the protein treatment were more likely to be compliant compared to the
carbohydrate-supplemented group, then the magnitude for the association between BMD levels
and the treatment effect might have been overestimated. Therefore, understanding the
mechanisms behind compliance is essential to establishing clinical efficacy.

While there were no significant predictors of compliance group membership in the multinomial
logistic models, reported adverse events was found to be a significant predictor in the standard
logistic regression models. Subjects who had reported an adverse event throughout the trial were
more likely to be compliant with their treatment. This makes intuitive sense because subjects
who believe that they are more susceptible to having lower BMD because of an adverse event
19

will more likely comply with the medication in hopes of increasing their BMD levels. This idea
is known as the Becker’s health belief model. It postulates that the likelihood that patients follow
a health regimen is related to their motivation and incentive to do so.35 The motivation and
incentive, in this case, is alleviating their adverse event, and so subjects are more likely to
comply with the protein or carbohydrate supplements.

In summary, the analysis using the GBTM methodology will provide supplementation to the
clinical trial to explain how efficacy is driven by compliance. By identifying the differential
effects in reporting an adverse event at baseline and its impact on compliance, subgroup analysis
can be performed to compare BMD levels over time between subjects who did and did not
reported an adverse event at baseline. If it is shown that subjects who reported an adverse event
had a greater treatment difference of increased BMD compared to those who did not report an
adverse event, then future studies can be develop to target subjects with adverse events. But
because of the low sample size and the risk of type I error, subgroup analysis should be
approached with caution; these analysis are merely speculative and must be followed up with
confirmatory studies16 Nevertheless, exploring trajectory groups using GBTM is advantageous in
identifying more direct thresholds of compliance for establishing clinical efficacy.
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Table 1. Description of the Samplea
Characteristic
Age (years)
Gender
Male
Female
Study Site
Yale
UCHC
DEXA L2-4 BMD (g/cm2)
T-score
≤ -2.5
> -2.5
Adverse Event
Yes
No
EPESE Score
History of Depression/ Anxiety
Yes
No
a
b

N = 208b
69.8 ± 6.2
30 (14.4)
178 (85.6)
66 (31.7)
142 (68.3)
1.2 ± 0.2
16 (7.8)
188 (92.2)
82 (39.4)
126 (60.6)
11.3 ± 1.1
23 (13.3)
150 (86.7)

Table values are mean ± SD for continuous variables and n (%) for categorical variables
Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding
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Table 2. Model Selection using BIC, Log Bayes Factor, and Estimated Group Proportions Using
GBTM in Determining Compliance Trajectory Groups

Number of
Groups
1
2
3
4
5

BIC

Log Bayes
Factor

-4328.50
-3755.63
-3722.41
-3602.30
-3589.89

1145.74
66.44
240.22
24.82

Estimated Group Proportions
Group 2
Group 3
Group 4

Group 1
100.00
41.98
40.93
23.50
23.62

58.02
16.09
36.87
2.14

42.98
19.81
19.29

Group 5

19.82
41.05

13.90

Table 3. Final Model Containing the 4-Group Compliance Trajectories
Group
Severely Noncompliant
Intercept
Linear
Delayed Noncompliant
Intercept
Linear
Quadratic
Moderately Compliant
Intercept
Near-Perfect Compliant
Intercept
a

Parameter Estimatea
(95% CI)

t-statistic

P-value

170.19 (112.87 , 227.51)
-52.60 (-70.43 , -34.77)

5.82
-5.78

< 0.001
< 0.001

33.84 (-38.66 , 106.34)
31.96 (-0.13 , 64.05)
-6.15 (-9.48 , -2.82)

0.92
1.95
-3.62

0.361
0.051
< 0.001

76.75 (71.35 , 82.15)

27.88

< 0.001

114.98 (103.31 , 126.65)

31.47

< 0.001

Parameter estimates denote the differential time polynomial

Table 4. Model Diagnostics for GBTM
Group
Severely Noncompliant
Delayed Noncompliant
Moderately Compliant
Near-Perfect Compliant
a
b

Group Membership Model
Estimates (95% CI)
0.24 (0.17 , 0.30)
0.20 (0.14 , 0.26)
0.37 (0.26 , 0.48)
0.20 (0.09 , 0.30)

Proportion
Classified in Group
0.24
0.20
0.37
0.20

Average Posterior
Probabilitya
0.979
0.964
0.917
0.858

Odds of Correct
Classificationb
156
107
19
24

Average posterior probability for each group should exceed the minimum threshold of 0.7
Minimum odds of correct classification should exceed 5
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Table 5. Description of the Sample by Compliance Trajectory Group

Characteristic

Age
Gender
Male
Female
Study Site
Yale
UCHC
DEXA L2-4 BMD
(g/cm2)
T-score
≤ -2.5
> -2.5
Adverse Event
Yes
No
EPESE Score
History of
Depression/ Anxiety
Yes
No

Compliance Trajectory Groupsab
Severely
Delayed
Moderately
Noncompliant
Noncompliant
Compliant
(n = 49)
(n = 41)
(n = 76)
70.3 ± 6.7
69.0 ± 6.3
69.6 ± 6.4

Near-Perfect
Compliant
(n = 42)
70.6 ± 5.1

7 (14.3)
42 (85.7)

3 (7.3)
38 (92.7)

9 (11.8)
67 (88.2)

11 (26.2)
31 (73.8)

15 (30.6)
34 (69.4)
1.1 ± 0.2

14 (34.2)
27 (65.9)
1.1 ± 0.2

25 (32.9)
51 (67.1)
1.2 ± 0.3

12 (28.6)
30 (71.4)
1.2 ± 0.2

7(14.6)
41 (85.4)

3 (7.7)
36 (92.3)

4 (5.3)
71 (94.7)

2 (4.8)
40 (95.2)

P-valuec

0.639
0.079

0.944

0.092
0.268

0.198
16 (32.7)
33 (67.4)
11.3 ± 1.2

22 (53.7)
19 (46.3)
11.2 ± 1.4

28 (36.8)
48 (63.2)
11.4 ± 0.9

16 (38.1)
26 (61.9)
11.3 ± 1.1

5 (12.2)
36 (87.8)

8 (23.5)
26 (76.5)

6 (9.4)
58 (90.6)

4 (11.8)
30 (88.2)

0.719
0.283

a

Table values are mean ± SD for continuous variables and n (%) for categorical variables
Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding
c
P-values are calculated using the Pearson Chi-Square or Fisher’s Exact test for categorical variables and One-Way
ANOVA for continuous variables
b

23

Table 6. Multinomial Logistic Regression Model 1: Predictors of Compliance Group Membership (N = 168)ab
Severely Noncompliant
AOR
95% CI
1.04
(0.95 , 1.13)
0.31
(0.08 , 1.27)
0.86
(0.23 , 3.30)
3.36
(0.58 , 19.34)
0.76
(0.28 , 2.08)
0.95
(0.60 , 1.51)
1.12
(0.27 , 4.71)

Delayed Noncompliant
AOR
95% CI
1.00
(0.91 , 1.09)
0.28
(0.06 , 1.37)
1.62
(0.44 , 6.01)
0.81
(0.09 , 7.06)
2.27
(0.81 , 6.34)
0.85
(0.53 , 1.36)
2.34
(0.60 , 9.07)

Variable
Age
Gender
Study Site
Osteoporosis (T-score)
Adverse Event
EPESE Score
History of Depression/
Anxiety
a
Near-perfect compliant group was set as the reference group
b 2
R = 0.153; max-rescaled R2 =0.164

Moderately Compliant
AOR
95% CI
1.04
(0.96 , 1.12)
0.35
(0.10 , 1.16)
1.98
(0.64 , 6.19)
0.40
(0.05 , 3.18)
0.71
(0.29 , 1.76)
1.14
(0.73 , 1.79)
0.71
(0.17 , 2.90)

Wald χ23
1.57
4.40
2.74
6.96
6.88
1.89
3.79

P-value
0.666
0.222
0.433
0.073
0.076
0.596
0.285

Table 7. Multinomial Logistic Regression Model 2: Predictors of Compliance Group Membership (N = 168)ab
Severely Noncompliant
AOR
95% CI
1.04
(0.95 , 1.14)
0.36
(0.08 , 1.53)
0.97
(0.26 , 3.62)
0.26
(0.02 , 3.89)
0.69
(0.26 , 1.87)
0.94
(0.60 , 1.47)
1.13
(0.27 , 4.73)

Delayed Noncompliant
AOR
95% CI
1.00
(0.91 , 1.10)
0.31
(0.06 , 1.55)
1.44
(0.38 , 5.47)
0.64
(0.04 , 11.02)
2.27
(0.81 , 6.35)
0.85
(0.53 , 1.36)
2.30
(0.59 , 8.94)

Variable
Age
Gender
Study Site
DEXA L2-4 BMD (g/cm2)
Adverse Event
EPESE Score
History of Depression/
Anxiety
a
Near-perfect compliant group was set as the reference group
b 2
R = 0.162; max-rescaled R2 = 0.173

Moderately Compliant
AOR
95% CI
1.02
(0.94 , 1.11)
0.26
(0.07 , 0.94)
2.35
(0.73 , 7.57)
6.66
(0.67 , 65.8)
0.77
(0.31 , 1.91)
1.18
(0.74 , 1.86)
0.71
(0.17 , 2.90)

Wald χ23
1.22
4.76
3.45
8.56
6.94
2.24
3.70

P-value
0.748
0.190
0.328
0.036
0.074
0.524
0.296
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Table 8. Logistic Regression Model 1 (N = 168)abc
Variable
AOR (95% Confidence Interval)
Age
1.04 (0.98 , 1.10)
Gender
0.55 (0.21 , 1.44)
Study Site
1.19 (0.53 , 2.68)
Osteoporosis (T-score)
1.39 (0.38 , 5.03)
Adverse Event
0.49 (0.25 , 0.94)
EPESE Score
1.15 (0.84 , 1.57)
History of Depression/ Anxiety
0.53 (0.21 , 1.33)
a
Adjusted odds ratios compared noncompliant to compliant group
b 2
R = 0.055; max-rescaled R2 =0.075
c
Hosmer and Lemeshow Goodness of Fit χ28 = 4.868, p-value = 0.772

P-value
0.224
0.222
0.680
0.617
0.033
0.388
0.172

Table 9. Logistic Regression Model 2 (N = 168)abc
Variable
AOR (95% Confidence Interval)
Age
1.03 (0.97 , 1.09)
Gender
0.46 (0.17 , 1.27)
Study Site
1.42 (0.62 , 3.25)
DEXA L2-4 BMD (g/cm2)
2.54 (0.46 , 13.94)
Adverse Event
0.49 (0.26 , 0.95)
EPESE Score
1.14 (0.84 , 1.56)
History of Depression/ Anxiety
0.54 (0.21 , 1.35)
a
Adjusted odds ratios compared noncompliant to compliant group
b 2
R = 0.060; max-rescaled R2 = 0.082
c
Hosmer and Lemeshow Goodness of Fit χ28 = 4.484, p-value = 0.811

P-value
0.344
0.134
0.407
0.283
0.035
0.403
0.185
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Figure 1. Individual Trajectories of Percent Compliance by Visita

a

Individual trajectories were plotted over the seven time points (visits) overlaid by a spline function

Figure 2. Four-Group Compliance Trajectories using GBTMa

a

Dashed lines denote the fitted model using GBTM and the solid lines denote the mean percent compliance at each
time point
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Figure 3. One-, Two-, Three-, and Five-Group Compliance Trajectories using GBTMa

a

Dashed lines denote the fitted model using GBTM and the solid lines denote the mean percent compliance at each time point
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